Lantern Pharma (LTRN) Competitors

$3.13 +0.62 (+24.70%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 +0.04 (+1.44%)

As of 07:54 PM Eastern

LTRN vs. KALA, COYA, PMN, NRXP, and AADI

Should you buy Lantern Pharma stock or one of its competitors? MarketBeat compares Lantern Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lantern Pharma include KALA BIO (KALA), Coya Therapeutics (COYA), Promis Neurosciences (PMN), NRx Pharmaceuticals (NRXP), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

How does Lantern Pharma compare to KALA BIO?

Lantern Pharma (NASDAQ:LTRN) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Lantern Pharma's return on equity of -150.76% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-150.76%	-108.38%
KALA BIO	N/A	-12,971.16%	-90.83%

Lantern Pharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.57	N/A
KALA BIO	N/A	N/A	-$26.98M	-$166.50	N/A

In the previous week, Lantern Pharma had 4 more articles in the media than KALA BIO. MarketBeat recorded 7 mentions for Lantern Pharma and 3 mentions for KALA BIO. Lantern Pharma's average media sentiment score of 0.37 beat KALA BIO's score of 0.07 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lantern Pharma has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.23, suggesting that its share price is 323% less volatile than the broader market.

KALA BIO has a consensus price target of $1,018.75, indicating a potential upside of 32,869.26%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Lantern Pharma beats KALA BIO on 8 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Lantern Pharma has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Lantern Pharma	N/A	-150.76%	-108.38%

Lantern Pharma has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	15.52	-$21.23M	-$1.27	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.57	N/A

In the previous week, Coya Therapeutics had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 8 mentions for Coya Therapeutics and 7 mentions for Lantern Pharma. Coya Therapeutics' average media sentiment score of 0.64 beat Lantern Pharma's score of 0.37 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

Coya Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 204.18%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Coya Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Coya Therapeutics beats Lantern Pharma on 11 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Promis Neurosciences presently has a consensus price target of $26.50, indicating a potential upside of 150.47%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Promis Neurosciences is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lantern Pharma's return on equity of -150.76% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Lantern Pharma	N/A	-150.76%	-108.38%

Promis Neurosciences has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

Lantern Pharma is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$19.00	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.57	N/A

In the previous week, Lantern Pharma had 3 more articles in the media than Promis Neurosciences. MarketBeat recorded 7 mentions for Lantern Pharma and 4 mentions for Promis Neurosciences. Lantern Pharma's average media sentiment score of 0.37 beat Promis Neurosciences' score of -0.28 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantern Pharma beats Promis Neurosciences on 8 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to NRx Pharmaceuticals?

Lantern Pharma (NASDAQ:LTRN) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

NRx Pharmaceuticals has a consensus price target of $38.25, suggesting a potential upside of 1,091.59%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NRx Pharmaceuticals' return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-150.76%	-108.38%
NRx Pharmaceuticals	N/A	N/A	-265.03%

Lantern Pharma has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Lantern Pharma has higher earnings, but lower revenue than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.57	N/A
NRx Pharmaceuticals	$1.23M	86.30	-$28.62M	-$1.39	N/A

In the previous week, Lantern Pharma had 4 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 7 mentions for Lantern Pharma and 3 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.65 beat Lantern Pharma's score of 0.37 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantern Pharma and NRx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Lantern Pharma compare to Aadi Bioscience?

Lantern Pharma (NASDAQ:LTRN) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Lantern Pharma has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-150.76%	-108.38%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Lantern Pharma has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.57	N/A
Aadi Bioscience	$25.07M	4.86	-$65.76M	-$2.35	N/A

Lantern Pharma has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Lantern Pharma had 6 more articles in the media than Aadi Bioscience. MarketBeat recorded 7 mentions for Lantern Pharma and 1 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.67 beat Lantern Pharma's score of 0.37 indicating that Aadi Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aadi Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lantern Pharma beats Aadi Bioscience on 7 of the 13 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LTRN vs. The Competition

Export

Metric	Lantern Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.38M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-1.99	18.47	20.90	25.61
Price / Sales	N/A	296.18	549.93	78.79
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	5.40	6.93	9.93	6.96
Net Income	-$17.12M	$24.11M	$3.55B	$333.52M
7 Day Performance	53.43%	0.08%	-0.33%	0.45%
1 Month Performance	34.33%	0.84%	1.34%	4.06%
1 Year Performance	-22.91%	78.10%	41.10%	36.24%

Lantern Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LTRN Lantern Pharma	0.6022 of 5 stars	$3.13 +24.7%	N/A	-38.9%	$28.38M	N/A	N/A	20	Upcoming Earnings Insider Trade High Trading Volume
KALA KALA BIO	2.2974 of 5 stars	$0.11 +1.9%	$20.38 +18,422.7%	-98.2%	$100.39M	N/A	N/A	30	Stock Split
COYA Coya Therapeutics	2.9923 of 5 stars	$4.25 -0.2%	$16.00 +276.5%	-21.2%	$99.93M	$7.95M	N/A	6	News Coverage Earnings Report
PMN Promis Neurosciences	2.6548 of 5 stars	$11.06 -0.1%	$42.67 +285.8%	-18.7%	$99.27M	N/A	N/A	5	Earnings Report
NRXP NRx Pharmaceuticals	2.9012 of 5 stars	$3.04 +1.3%	$38.25 +1,158.2%	+28.8%	$99.20M	$1.23M	N/A	2	Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LTRN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantern Pharma (LTRN) Competitors

LTRN vs. KALA, COYA, PMN, NRXP, and AADI

How does Lantern Pharma compare to KALA BIO?

Summary

How does Lantern Pharma compare to Coya Therapeutics?

Summary

How does Lantern Pharma compare to Promis Neurosciences?

Summary

How does Lantern Pharma compare to NRx Pharmaceuticals?

Summary

How does Lantern Pharma compare to Aadi Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantern Pharma (LTRN) Competitors

LTRN vs. KALA, COYA, PMN, NRXP, and AADI

How does Lantern Pharma compare to KALA BIO?

Is LTRN or KALA more profitable?

Which has preferable earnings & valuation, LTRN or KALA?

Does the media refer more to LTRN or KALA?

Which has more volatility & risk, LTRN or KALA?

Do analysts recommend LTRN or KALA?

Do insiders and institutionals have more ownership in LTRN or KALA?

Summary

How does Lantern Pharma compare to Coya Therapeutics?

Is COYA or LTRN more profitable?

Which has higher valuation & earnings, COYA or LTRN?

Does the media prefer COYA or LTRN?

Which has more risk and volatility, COYA or LTRN?

Do analysts prefer COYA or LTRN?

Do institutionals and insiders have more ownership in COYA or LTRN?

Summary

How does Lantern Pharma compare to Promis Neurosciences?

Do analysts prefer PMN or LTRN?

Do institutionals and insiders have more ownership in PMN or LTRN?

Is PMN or LTRN more profitable?

Which has more risk and volatility, PMN or LTRN?

Which has higher valuation & earnings, PMN or LTRN?

Does the media prefer PMN or LTRN?

Summary

How does Lantern Pharma compare to NRx Pharmaceuticals?

Do analysts rate LTRN or NRXP?

Do institutionals and insiders have more ownership in LTRN or NRXP?

Is LTRN or NRXP more profitable?

Which has more volatility & risk, LTRN or NRXP?

Which has stronger valuation and earnings, LTRN or NRXP?

Does the media favor LTRN or NRXP?

Summary

How does Lantern Pharma compare to Aadi Bioscience?

Is LTRN or AADI more profitable?

Which has preferable earnings & valuation, LTRN or AADI?

Which has more risk & volatility, LTRN or AADI?

Do analysts rate LTRN or AADI?

Does the media favor LTRN or AADI?

Do insiders & institutionals believe in LTRN or AADI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools